The deal would fold the FDA-cleared Hotwire system, and the team behind Farapulse, into J&J’s expanding cardiac ablation business.
The TAVVE study will begin later this year with ten patients, whose 30-day safety results will be submitted to the FDA.
Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe.
CathWorks FFRangio System employs drug-free, wire-free technology for comprehensive physiological assessment.
MedTech leaders must find a balance between the slow, careful world of medicine and the fast-paced expectations of investors. Real success comes from choosing high-quality science over quick shortcuts, as being thorough is the only way to build lasting trust and reach the market.
New pathway cuts red tape and brings predictability to Medicare coverage for Breakthrough Devices.
Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Traditionally, contract negotiation has been viewed as a financial or legal responsibility, typically led by finance teams, legal counsel, or executive leadership, with operations stepping in afterward to execute against decisions that have already been made, but that model is evolving as healthcare delivery becomes more interconnected and operationally complex, requiring administrators to engage earlier in the process, not only to understand what is being agreed to but to help define how those agreements will function in real-world environments.
Companies and researchers often fail to disclose negative trial results, resulting in significant gaps in the public record and a publication bias that obscures the true landscape of drug development outcomes—overrepresenting successes and underrepresenting failures. This gap can also create a distorted perception of the safety and efficacy of medical products.
Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, this next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease, according to the company.